Stability-indicating thin-layer chromatographic method for quantitative determination of ribavirin.

A simple and accurate stability-indicating thin-layer chromatographic (TLC) method is developed and validated for the quantitative determination of ribavirin (RBV) in its bulk and with used for development consists of chloroform-methanol-acetic acid (60:15:15, v/v/v). The separated spots are visualized as bluish green spots after being sprayed with anisaldehyde reagent. RBV is subjected to different accelerated stress conditions. The drug is found to undergo degradation under all stress conditions, and the degradation products are well resolved from the pure drug with significantly different Rf values. The optical densities of the separated spots are found to be linear with the amount of RBV in the range of 5-40 microg/spot with a good correlation coefficient (r=0.9980). The limit of detection and limit of quantitation values are 1.40 and 4.67 microg/spot, respectively. Statistical analysis proves that the method is repeatable and accurate for the determination of RBV in the presence of its degradation products. The method meets the International Conference on Harmonisation/Food and Drug Administration regulatory requirements. The proposed TLC method is successfully applied for the determination of RBV, pure and in capsules, with good accuracy and precision; the label claim percentages are 98.8%+/-1.5%. The results obtained by the proposed TLC method are comparable with those obtained by the official method.

[1]  Sarfaraz K Niazi Stability Data Package for Registration Applications in Climatic Zones III and IV , 2009 .

[2]  I. Darwish,et al.  Application of inorganic oxidants to the spectrophotometric determination of ribavirin in bulk and capsules. , 2006, Journal of AOAC International.

[3]  I. Darwish,et al.  Simple fluorimetric method for determination of certain antiviral drugs via their oxidation with cerium (IV). , 2005, Farmaco.

[4]  M. Breadmore,et al.  Determination of ribavirin in human serum and plasma by capillary electrophoresis , 2004, Electrophoresis.

[5]  J. McHutchison,et al.  New therapies for chronic hepatitis C virus infection , 2004, Current gastroenterology reports.

[6]  Karen M. Alsante,et al.  Handbook of Isolation and Characterization of Impurities in Pharmaceuticals , 2003 .

[7]  L. Yeh,et al.  A sensitive and specific method for the determination of total ribavirin in human red blood cells by liquid chromatography-tandem mass spectrometry. , 2003, Journal of chromatographic science.

[8]  A. Bruchfeld,et al.  Determination of ribavirin in serum using highly selective solid-phase extraction and high-performance liquid chromatography. , 2000, Therapeutic drug monitoring.

[9]  A. M. Battaglia,et al.  Combination Therapy with Interferon and Ribavirin in the Treatment of Chronic Hepatitis C Infection , 2000, The Annals of pharmacotherapy.

[10]  F. Aweeka,et al.  High-Performance Liquid Chromatographic Determination of Ribavirin in Whole Blood To Assess Disposition in Erythrocytes , 1999, Antimicrobial Agents and Chemotherapy.

[11]  C. Lakshmi,et al.  Application of sodium metaperiodate for the determination of ribavirin in pharmaceutical formulations. , 1998, Talanta.

[12]  S. Ahuja Impurities evaluation of pharmaceuticals , 1998 .

[13]  M. Chevallier,et al.  Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation , 1997, Hepatology.

[14]  C. Blot,et al.  Effects of cirrhosis, interferon and azathioprine on adverse events in patients with chronic hepatitis C treated with ribavirin , 1997, Journal of viral hepatitis.

[15]  C. Riley,et al.  Chromatographic methods for the bioanalysis of antiviral agents. , 1990, Journal of chromatography.

[16]  M. Kagnoff,et al.  Sensitive radioimmunoassay for the broad-spectrum antiviral agent ribavirin , 1983, Antimicrobial Agents and Chemotherapy.

[17]  J. B. Jerome The United States Pharmacopeia, ed 20; The National Formulary , 1981 .

[18]  D. Dieterich,et al.  Activity of combination therapy with interferon alfa-2b plus ribavirin in chronic hepatitis C patients co-infected with HIV. , 1999, Seminars in liver disease.

[19]  J. Mcginity Drug Stability: Principles and Practices , 1991 .